PACB vs. EDIT

In the year-to-date period, PACB achieves a -81.96% return, which is significantly lower than EDIT's -76.60% return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Pacific Biosciences of California, Inc. (PACB) and Editas Medicine, Inc. (EDIT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current PACB Sharpe Ratio is -0.67, which is higher than the EDIT Sharpe Ratio of -1.10. The chart below compares the historical Sharpe Ratios of PACB and EDIT, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither PACB nor EDIT has paid dividends to shareholders.

The maximum PACB drawdown since its inception was -97.65%, roughly equal to the maximum EDIT drawdown of -97.38%. Use the drawdown chart below to compare losses from any high point for PACB and EDIT. For additional features, visit the drawdowns tool.

Pacific Biosciences of California, Inc. (PACB) has a higher volatility of 33.77% compared to Editas Medicine, Inc. (EDIT) at 18.19%. This indicates that PACB's price experiences larger fluctuations and is considered to be riskier than EDIT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Pacific Biosciences of California, Inc. and Editas Medicine, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.